NELFCD and Zygomycosis: Our data also extend previous observations showing that 1) deferasirox treatment enhanced the host inflammatory response to mucormycosis [11], and 2) ADA therapy is able to increase the secretion of Th-1 pro-inflammatory cytokines, enhancing allogeneic T-cell proliferation and immunogenicity [6].